Jefferies Group’s Coherus Oncology CHRS Stock Holding History

Jefferies Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-70,000	Closed	-$1.42M	–	2603
2019 Q3	$1.42M	Hold	70,000	–	–	0.01%	1296
2019 Q2	$1.55M	Buy	+70,000	New	+$1.22M	0.01%	1064

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jefferies Group's CHRS Position: Q1 2022 in Review

Jefferies Group sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 19,128 shares — an estimated $305K sold.

Jefferies Group first reported a position in CHRS in Q2 2016 and held it in 11 quarters. The position peaked at $1.53M in Q2 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

Jefferies Group reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 19,128 Coherus Oncology shares in Q1 2022, an estimated $305K.
Jefferies Group first reported a position in Coherus Oncology in Q2 2016 and held it in 11 quarters.
Jefferies Group's Coherus Oncology position peaked at $1.53M in Q2 2021.
183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.